Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Amphastar Pharmaceuticals, Inc. (AMPH) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $24.75 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $24.75.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $24.85.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $25.58.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $25.49.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $24.75 10-Q · filed 2026-08-06 |
| 2026-03-31 | $24.85 10-Q · filed 2026-05-07 |
| 2025-12-31 | $25.58 10-K · filed 2026-02-26 |
| 2025-09-30 | $25.49 10-Q · filed 2025-11-06 |
| 2025-06-30 | $25.40 10-Q · filed 2025-08-07 |
| 2025-03-31 | $24.94 10-Q · filed 2025-05-08 |
| 2024-12-31 | $23.43 10-K · filed 2025-03-03 |
| 2024-09-30 | $23.24 10-Q · filed 2024-11-07 |
| 2024-06-30 | $23.00 10-Q · filed 2024-08-09 |
| 2024-03-31 | $22.55 10-Q · filed 2024-05-10 |
| 2023-12-31 | $19.46 10-K · filed 2024-02-29 |
| 2023-09-30 | $19.37 10-Q · filed 2023-11-08 |
| 2023-06-30 | $19.27 10-Q · filed 2023-08-09 |
| 2023-03-31 | $18.83 10-Q · filed 2023-05-09 |
| 2022-12-31 | $17.51 10-K · filed 2023-03-01 |
| 2022-09-30 | $17.45 10-Q · filed 2022-11-08 |
| 2022-06-30 | $17.42 10-Q · filed 2022-08-09 |
| 2022-03-31 | $17.20 10-Q · filed 2022-05-10 |
| 2021-12-31 | $15.64 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |